Using both genetic and pharmacological approaches, we have produced evidence supporting the idea that enhanced and prolonged activation of astrocytes plays a detrimental role in the pathogenesis of cerebral ischemia and AD, and that astroctye-derived S100B is at the epicenter of these damaging cellular responses. The gene discussed is S100B; the disease is brain ischemia.